Aplagon is developing a vascular injury targeting, locally acting antithrombotic product.
Aplagon is developing a vascular injury targeting, locally acting antithrombotic product (APAC) about to enter clinical studies in hemodialysis access failure and COVID-19. We are partnered with a large Indian pharmaceutical company for the clinical development and commercialisation of APAC in India.
Aplagon is based on the pioneering research performed by Prof. Riitta Lassila’s group at Wihuri Research Institute in Helsinki, Finland on mast cell-derived heparin proteoglycans (HEP-PG). These early HEP-PG discoveries led to Aplagon’s product, APAC, a heparin proteoglycan mimetic. After years of hard work, APAC is now moving to clinical studies. Aplagon’s goal is to demonstrate preliminary efficacy and safety of APAC in patients in two indications in 2021-2022.